Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review

Sandra, Irina; Cazacu, Irina M.; Croitoru, Vlad Mihai; Mihaila, Mariana; Herlea, Vlad; Diculescu, Mircea; Dima, Simona; Croitoru, Adina

doi:10.3390/cimb44090274

Cited by 5 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF signalling pathways in NENs are one of the most studied angiogenic factors. Controversial conclusions have been obtained from the analysed data [ 29 ]. Some studies showed higher VEGF levels in NET patients compared to healthy controls, however, with a lack of correlation between grading and aggressiveness [ 10 , 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

2023

View full text Add to dashboard Cite

Angiogenic factors (AF) promote vascular formation and may thus support neuroendocrine tumour (NET) development. This study aimed to assess AF serum level changes in NET patients treated with prolonged-acting somatostatin analogues (SSAs). The study enrolled 49 healthy volunteers (Group A) and 56 NET patients: treatment naïve (Group B) and after-SSA treatment in various periods (months): under 12 (Group C), 13–24 (Group D), 25–36 (Group E), 37–60 (Group F), and over 60 months (Group G). The serum vascular endothelial growth factor receptors 2, 3 (VEGF-R2, VEGF-R3), and vascular cell adhesion molecule-1 (VCAM-1) concentrations were tested using the ELISA. We noted significant differences in the concentrations of VEGF-R2, VEGF-R3, and VCAM-1 depending on the SSA treatment duration (p < 0.001). In the studied AFs, the highest decreasing levels of VEGF-R2 were observed after two years of therapy. However, monitoring VEGF-R2, VEGF-R3, and VCAM-1 during SSA treatment did not allow for the identification of good responders for this kind of therapy. Therefore, these biomarker measurements were not helpful in assessing SSA treatment effectiveness in NET patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

2023

View full text Add to dashboard Cite

show abstract

“…On the other hand, placental growth factor, angiopoietin 2, and IL-8 were found to be good predictors of unfavorable outcomes and aggressive disease behavior. However, there is currently no evidence to use them as routine markers in the clinic [109].…”

Section: Other Biomarkersmentioning

confidence: 99%

An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide

Bevere,

Masetto,

Carazzolo

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) are a heterogeneous group of diseases that are characterized by different behavior and clinical manifestations. The diagnosis and management of this group of tumors are challenging due to tumor complexity and lack of precise and widely validated biomarkers. Indeed, the current circulating mono-analyte biomarkers (such as chromogranin A) are ineffective in describing such complex tumors due to their poor sensitivity and specificity. In contrast, multi-analytical circulating biomarkers (including NETest) are emerging as more effective tools to determine the real-time profile of the disease, both in terms of accurate diagnosis and effective treatment. In this review, we will analyze the capabilities and limitations of different circulating biomarkers focusing on three relevant questions: (1) accurate and early diagnosis; (2) monitoring of disease progression and response to therapy; and (3) detection of early relapse.

show abstract

Circulating biomarkers in perioperative management of cancer patients

Huang

Zhou

Hao

et al. 2023

Precision Clinical Medicine

View full text Add to dashboard Cite

Owing to the advances in surgical technology, most solid tumors can be controlled by surgical excision. The priority should be tumor control, while some routine perioperative management might influence cancer progression in an unnoticed way. Moreover, it is increasingly recognized that effective perioperative management should include techniques to improve postoperative outcomes. These influences are elucidated by the different functions of circulating biomarkers in cancer patients. Here, circulating biomarkers with two types of clinical functions were reviewed: a) circulating biomarkers for cancer progression monitoring, for instance, those related to cancer cell malignancy, tumor microenvironment formation, and early metastasis, and b) circulating biomarkers with relevance to postoperative outcomes, including systemic inflammation, immunosuppression, cognitive dysfunction, and pain management. This review aimed to provide new perspectives for the perioperative management of patients with cancer and highlight the potential clinical translation value of circulating biomarkers in improving outcomes.

show abstract

Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review

Cited by 5 publications

References 60 publications

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide

Circulating biomarkers in perioperative management of cancer patients

Contact Info

Product

Resources

About